MedTrace Logo

Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer

NCT00042510 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2014-08-28

No results posted yet for this study

Summary

This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for gastric cancer.

Conditions

  • Stomach Neoplasms
  • Esophageal Neoplasms

Interventions

BIOLOGICAL

Treatment group

Sponsors & Collaborators

  • Cancer Advances Inc.

    lead INDUSTRY

Principal Investigators

  • Jaffer A Ajani, M.D. · U.S. studies

  • Vladimir Moiseyenko, M.D., Ph.D · Non U.S. studies

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-08-31
Primary Completion
2003-02-28
Completion
2004-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00042510 on ClinicalTrials.gov